Connor Clark & Lunn Investment Management Ltd. Has $4.40 Million Stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Connor Clark & Lunn Investment Management Ltd. grew its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 1.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 555,655 shares of the company’s stock after purchasing an additional 6,680 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned about 0.18% of Amneal Pharmaceuticals worth $4,401,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of AMRX. Aigen Investment Management LP acquired a new stake in Amneal Pharmaceuticals in the 3rd quarter worth $213,000. Victory Capital Management Inc. boosted its position in shares of Amneal Pharmaceuticals by 58.7% during the 3rd quarter. Victory Capital Management Inc. now owns 99,215 shares of the company’s stock valued at $825,000 after acquiring an additional 36,700 shares in the last quarter. Gladius Capital Management LP acquired a new stake in shares of Amneal Pharmaceuticals during the 3rd quarter valued at about $37,000. Quest Partners LLC acquired a new stake in shares of Amneal Pharmaceuticals during the 3rd quarter valued at about $84,000. Finally, Segall Bryant & Hamill LLC boosted its position in shares of Amneal Pharmaceuticals by 1.6% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 489,162 shares of the company’s stock valued at $4,070,000 after acquiring an additional 7,661 shares in the last quarter. 31.82% of the stock is currently owned by institutional investors and hedge funds.

Amneal Pharmaceuticals Stock Down 0.5 %

Shares of AMRX stock opened at $8.75 on Monday. Amneal Pharmaceuticals, Inc. has a 12-month low of $5.18 and a 12-month high of $9.48. The company has a market capitalization of $2.71 billion, a P/E ratio of -12.87 and a beta of 1.05. The firm has a 50-day moving average price of $8.30 and a 200 day moving average price of $8.36.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its earnings results on Friday, February 28th. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.03). Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. The company had revenue of $730.52 million during the quarter, compared to the consensus estimate of $708.21 million. During the same period in the prior year, the firm posted $0.14 earnings per share. As a group, research analysts expect that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently weighed in on AMRX shares. JPMorgan Chase & Co. upgraded shares of Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their target price for the company from $9.00 to $12.00 in a research report on Monday, February 24th. StockNews.com lowered shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, December 19th. Finally, Barclays lifted their price target on shares of Amneal Pharmaceuticals from $10.00 to $11.00 and gave the company an “overweight” rating in a report on Monday, March 3rd. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $10.80.

Insiders Place Their Bets

In other Amneal Pharmaceuticals news, Director Gautam Patel sold 62,590 shares of the business’s stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $8.01, for a total value of $501,345.90. Following the completion of the transaction, the director now directly owns 1,968,886 shares of the company’s stock, valued at approximately $15,770,776.86. The trade was a 3.08 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last three months, insiders sold 240,000 shares of company stock valued at $2,004,000. Insiders own 26.56% of the company’s stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.